AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECG TM software platform has ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

defined as 12-month freedom from a documented 30-second episode of Afib/atrial flutter/atrial tachycardia, failure of pulmonary vein isolation (PVI), cardioversion, antiarrhythmic drug use ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

In the single-arm PULSAR IDE study of 162 people, the novel PFA system demonstrated 78% primary effectiveness, defined as 12-month freedom from a documented 30-second episode of Afib/atrial ...

The China 3D cardiac mapping market has showcased significant growth, with its valuation increasing from $55.55 million in 2019 to a projected $150.59 million by 2027. This report offers a detailed ...

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need ...

All patients were free from AF or atrial flutter at baseline. Median follow-up was 2.9 years. “Atrial fibrillation is a very prevalent comorbidity in patients with heart failure, CKD and/or ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) system.

Boston Scientific today shared new clinical data supporting multiple therapies at the Heart Rhythm Society (HRS) 2025 Meeting in San Diego.

Unlike prior studies that focused solely on atrial fibrillation, this research is especially meaningful for its inclusion of a broad range of arrhythmias such as atrial flutter and atrial tachycardia.